Homepage
Medication Guide
What Are the Indications for Enasidenib?
Enasidenib is an oral isocitrate dehydrogenase-2 (IDH2) inhibitor, which was first approved for marketing in the United States in 2017 for the treatment of specific types of acute myeloid leukemia (AM...
511
Tuesday, December 23rd, 2025, 09:30
What Are the Procurement Channels for Enasidenib?
Enasidenib is a targeted drug indicated for relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutation, and its trade name is IDHIFA. Given its specific indications and prescription-only n...
504
Tuesday, December 23rd, 2025, 09:25
Adverse Reactions of Pralsetinib (Gavreto)
Pralsetinib (Gavreto) is a targeted therapy for RET fusion-positive tumors. While delivering therapeutic benefits to patients, it is also associated with potential risks that cannot be ignored.Adverse...
519
Monday, December 22nd, 2025, 09:44
What Are the Precautions for Pralsetinib (Gavreto) Administration?
Pralsetinib (Gavreto) is a new-generation highly selective RET inhibitor, offering a breakthrough treatment option for patients with RET fusion-positive non-small cell lung cancer and thyroid cancer.W...
507
Monday, December 22nd, 2025, 09:41
Dosage and Administration, Recommended Dose of Pralsetinib (Gavreto)
Pralsetinib (Gavreto) is a kinase inhibitor targeting RET gene fusions, and it demonstrates significant value in the treatment of metastatic RET fusion-positive non-small cell lung cancer and thyroid ...
509
Monday, December 22nd, 2025, 09:34
What Are the Indications for Pralsetinib (Gavreto)?
Pralsetinib (Gavreto) is an oral kinase inhibitor primarily indicated for the treatment of specific malignant tumors associated with RET gene alterations. Manufactured by Genentech, this drug first re...
507
Monday, December 22nd, 2025, 09:26
What Are the Purchase Channels for Pralsetinib (Gavreto)?
Pralsetinib (Gavreto) is a precision RET kinase inhibitor and has become an important treatment option for cancers associated with RET gene alterations. As a prescription medication, the purchase of p...
507
Monday, December 22nd, 2025, 09:20
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option for patients with estrogen receptor-positive, HER2-negative advanced or metastatic ...
510
Friday, December 19th, 2025, 11:49
What Are the Indications for Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of advanced breast cancer with specific gene mutations. As an estrogen receptor antagonist...
505
Friday, December 19th, 2025, 11:40
What Are the Purchase Channels for Elacestrant (Orserdu)?
With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific gene mutations, has brought new treatment options for patients. As the first oral sel...
507
Friday, December 19th, 2025, 11:38
31 / 214
2139 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved